Debio 0123

Preclinical

Debio 0123 is one of 3 therapeutic programs targeting Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Glioblastoma IDH (isocitrate Dehydrogenase) WildtypeRecruiting

Glioblastoma IDH (isocitrate Dehydrogenase) WildtypePreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Glioblastoma IDH (isocitrate Dehydrogenase) Wildtype

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

Debio 025

DDebiopharm International SA

Preclinical

1 3

Debio 0123

DDebiopharm International SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Glioblastoma IDH (isocitrate Dehydrogenase) Wildtype

NCT05765812

Clinical

Trials by Indication[1]

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype1 trial

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Recruiting·DDebiopharm International SA·Preclinical·NCT05765812·116 enrolled

Advanced Solid Tumors1 trial

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

Terminated·DDebiopharm International SA·Phase 1·NCT05109975·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Debio 0123. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Debio 0123. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: DDebiopharm International SA

Debio 0123

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News